Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.

A new series of phosphodiesterase-9 (PDE9) inhibitors that contain a scaffold of 6-amino-pyrazolopyrimidinone have been discovered by a combination of structure-based design and computational docking. This procedure significantly saved the load of chemical synthesis and is an effective method for the discovery of inhibitors. The best compound 28 has an IC(50) of 21 nM and 3.3 μM, respectively, for PDE9 and PDE5 and about 3 orders of magnitude of selectivity against other PDE families. The crystal structure of the PDE9 catalytic domain in complex with 28 has been determined and shows a hydrogen bond between 28 and Tyr424. This hydrogen bond may account for the 860-fold selectivity of 28 against PDE1B, in comparison with about 30-fold selectivity of BAY73-6691. Thus, our studies suggest that Tyr424, a unique residue of PDE8 and PDE9, is a potential target for improvement of selectivity of PDE9 inhibitors.

[1]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[2]  J. Jensen,et al.  Identification of phosphodiesterase 9A as a cyclic guanosine monophosphate-specific phosphodiesterase in germinal vesicle oocytes: a proposed role in the resumption of meiosis. , 2012, Fertility and sterility.

[3]  H. Ke,et al.  Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. , 2008, Biochemistry.

[4]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[5]  J. Mørland,et al.  Conditioned place preference induced by morphine and morphine-6-glucuronide in mice , 2006, Pharmacology Biochemistry and Behavior.

[6]  J. Takahashi,et al.  cAMP-Dependent Signaling as a Core Component of the Mammalian Circadian Pacemaker , 2008, Science.

[7]  A. Doweyko,et al.  Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[8]  David P. Rotella,et al.  INHIBITORS: CURRENT STATUS AND POTENTIAL APPLICATIONS , 2002 .

[9]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[10]  H. Sasano,et al.  Phosphodiesterase type 9 (PDE9) in the human lower urinary tract: an immunohistochemical study , 2012, BJU international.

[11]  Lynn A. Hyde,et al.  The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents , 2011, Neuropharmacology.

[12]  W. Zavadoski,et al.  The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents. , 2009, Bioorganic & medicinal chemistry letters.

[13]  K. Reymann,et al.  The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents , 2008, Neuropharmacology.

[14]  F. Menniti,et al.  Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. , 2012, Journal of medicinal chemistry.

[15]  Y. Itzhak,et al.  The effect of phosphodiesterase inhibitors on the extinction of cocaine-induced conditioned place preference in mice , 2012, Journal of psychopharmacology.

[16]  KenjiOmori,et al.  Overview of PDEs and Their Regulation , 2007 .

[17]  H. Ke,et al.  Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis. , 2010, Journal of medicinal chemistry.

[18]  K. Taskén,et al.  Spatiotemporal control of cAMP signalling processes by anchored signalling complexes. , 2007, Biochemical Society transactions.

[19]  Ajay N. Jain.  Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[20]  Hwa-Young Kim,et al.  Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. , 2003, Structure.

[21]  R. Schreiber,et al.  Improving memory: a role for phosphodiesterases. , 2006, Current pharmaceutical design.

[22]  Anne W. Schmidt,et al.  Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. , 2009, Journal of medicinal chemistry.

[23]  V. N. Molchanov,et al.  Superconducting Single Crystals of Tl2Ba2CaCu2O8 and YBa2Cu4O8: Crystal Structures in the Vicinity of Tc , 1998 .

[24]  P. Lemotte,et al.  Structural basis for the catalytic mechanism of human phosphodiesterase 9 , 2008, Proceedings of the National Academy of Sciences.

[25]  F. Antoni.  Molecular Diversity of Cyclic AMP Signalling , 2000, Frontiers in Neuroendocrinology.

[26]  C. Holt,et al.  The role of cyclic nucleotides in axon guidance. , 2007, Advances in experimental medicine and biology.

[27]  H. Rosenbrock,et al.  Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP , 2012, Neuropharmacology.

[28]  F. Menniti,et al.  Phosphodiesterases in the CNS: targets for drug development , 2006, Nature Reviews Drug Discovery.

[29]  W. Klein,et al.  Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. , 2007, Current Alzheimer research.

[30]  Manuela Zaccolo,et al.  of in The Role of the in the A Molecular for Generating cAMP and cGMP Signaling Cross-Talk Role of Phosphodiesterases and Implications for Cardiac Pathophysiology , 2007 .

[31]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[32]  Jiansong Fang,et al.  A New Protocol for Predicting Novel GSK-3β ATP Competitive Inhibitors , 2011, J. Chem. Inf. Model..

[33]  Hai-Bin Luo,et al.  Structural Asymmetry of Phosphodiesterase-9, Potential Protonation of a Glutamic Acid, and Role of the Invariant Glutamine , 2011, PloS one.

[34]  Wei Zhang,et al.  Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[36]  H. Ke,et al.  Multiple Conformations of Phosphodiesterase-5 , 2006, Journal of Biological Chemistry.

[37]  J. Uslaner,et al.  The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task , 2011, Journal of neurogenetics.

[38]  H. Ke,et al.  Structural insight into substrate specificity of phosphodiesterase 10 , 2007, Proceedings of the National Academy of Sciences.

[39]  T. Fahrig,et al.  Characterization of the First Potent and Selective PDE9 Inhibitor Using a cGMP Reporter Cell Line , 2005, Molecular Pharmacology.

[40]  B. Lipworth.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease , 2005, The Lancet.

[41]  H. Ke,et al.  Multiple Elements Jointly Determine Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases 4 and 7* , 2005, Journal of Biological Chemistry.

[42]  M. Pillinger,et al.  Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .

[43]  C. J. Schmidt.  Phosphodiesterase inhibitors as potential cognition enhancing agents. , 2010, Current topics in medicinal chemistry.

[44]  H. Ke,et al.  Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. , 2007, Current topics in medicinal chemistry.

[45]  M. Aghaei,et al.  Inhibition of phosphodiestrase 9 induces cGMP accumulation and apoptosis in human breast cancer cell lines, MCF‐7 and MDA‐MB‐468 , 2012, Cell proliferation.

[46]  Anne W. Schmidt,et al.  Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo , 2012, Journal of Pharmacology and Experimental Therapeutics.

[47]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.